These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 7856302)

  • 1. Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein.
    Mbawuike IN; Dillion SB; Demuth SG; Jones CS; Cate TR; Couch RB
    Vaccine; 1994 Nov; 12(14):1340-8. PubMed ID: 7856302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of protective class I MHC-restricted CTL in mice by a recombinant influenza vaccine in aluminium hydroxide adjuvant.
    Dillon SB; Demuth SG; Schneider MA; Weston CB; Jones CS; Young JF; Scott M; Bhatnaghar PK; LoCastro S; Hanna N
    Vaccine; 1992; 10(5):309-18. PubMed ID: 1349448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterosubtypic protective immunity against influenza A virus induced by fusion peptide of the hemagglutinin in comparison to ectodomain of M2 protein.
    Staneková Z; Király J; Stropkovská A; Mikušková T; Mucha V; Kostolanský F; Varečková E
    Acta Virol; 2011; 55(1):61-7. PubMed ID: 21434706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of a recombinant protein influenza A vaccine in adult human volunteers and protective efficacy against wild-type H1N1 virus challenge.
    Fries LF; Dillon SB; Hildreth JE; Karron RA; Funkhouser AW; Friedman CJ; Jones CS; Culleton VG; Clements ML
    J Infect Dis; 1993 Mar; 167(3):593-601. PubMed ID: 8440931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with the N-terminal region of the nonstructural protein NS1 promotes survival after challenge with lethal influenza A virus dose.
    Tamura M; Saikh KU; Kurane I; Ennis FA
    Viral Immunol; 1998; 11(3):131-5. PubMed ID: 9918404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection.
    Gocník M; Fislová T; Mucha V; Sládková T; Russ G; Kostolanský F; Varečková E
    J Gen Virol; 2008 Apr; 89(Pt 4):958-967. PubMed ID: 18343837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterosubtypic protection against influenza A induced by adenylate cyclase toxoids delivering conserved HA2 subunit of hemagglutinin.
    Staneková Z; Adkins I; Kosová M; Janulíková J; Sebo P; Varečková E
    Antiviral Res; 2013 Jan; 97(1):24-35. PubMed ID: 23036818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge.
    Epstein SL; Stack A; Misplon JA; Lo CY; Mostowski H; Bennink J; Subbarao K
    Int Immunol; 2000 Jan; 12(1):91-101. PubMed ID: 10607754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.
    Dong W; Bhide Y; Sicca F; Meijerhof T; Guilfoyle K; Engelhardt OG; Boon L; de Haan CAM; Carnell G; Temperton N; de Vries-Idema J; Kelvin D; Huckriede A
    Front Immunol; 2018; 9():2312. PubMed ID: 30356772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of CD8+ cytotoxic T cells by immunization with killed influenza virus and effect of cholera toxin B subunit.
    Mbawuike IN; Wyde PR
    Vaccine; 1993 Sep; 11(12):1205-13. PubMed ID: 7903015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
    Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
    PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The highly conserved HA2 protein of the influenza A virus induces a cross protective immune response.
    Lee JS; Chowdhury MY; Moon HJ; Choi YK; Talactac MR; Kim JH; Park ME; Son HY; Shin KS; Kim CJ
    J Virol Methods; 2013 Dec; 194(1-2):280-8. PubMed ID: 24004822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bivalent Heterologous DNA Virus-Like-Particle Prime-Boost Vaccine Elicits Broad Protection against both Group 1 and 2 Influenza A Viruses.
    Jiang W; Wang S; Chen H; Ren H; Huang X; Wang G; Chen Z; Chen L; Chen Z; Zhou P
    J Virol; 2017 May; 91(9):. PubMed ID: 28179535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine Efficacy of Inactivated, Chimeric Hemagglutinin H9/H5N2 Avian Influenza Virus and Its Suitability for the Marker Vaccine Strategy.
    Kim SM; Kim YI; Park SJ; Kim EH; Kwon HI; Si YJ; Lee IW; Song MS; Choi YK
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
    Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
    Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-Lasting Cross-Protection Against Influenza A by Neuraminidase and M2e-based immunization strategies.
    Schotsaert M; Ysenbaert T; Smet A; Schepens B; Vanderschaeghe D; Stegalkina S; Vogel TU; Callewaert N; Fiers W; Saelens X
    Sci Rep; 2016 Apr; 6():24402. PubMed ID: 27072615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unmasking Stem-Specific Neutralizing Epitopes by Abolishing N-Linked Glycosylation Sites of Influenza Virus Hemagglutinin Proteins for Vaccine Design.
    Liu WC; Jan JT; Huang YJ; Chen TH; Wu SC
    J Virol; 2016 Oct; 90(19):8496-508. PubMed ID: 27440889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection.
    To KK; Zhang AJ; Chan AS; Li C; Cai JP; Lau CC; Li CG; Jahan AS; Wu WL; Li L; Tsang AK; Chan KH; Chen H; Yuen KY
    Arch Virol; 2015 Mar; 160(3):777-86. PubMed ID: 25616843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.